Entities / Company
Amicus Therapeutics.
company in Cranbury, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 36
What's happening
Gone quiet
No new reports in 90+ days-
Amicus Therapeutics received drug approvals in multiple countries, including the US, Japan, Canada, and Switzerland.Some support3 reports1 development inside
-
Amicus Therapeutics received MHLW approval in Japan for Pombiliti + Opfolda treatment for LOPD.Speculative1 report
-
Okta operates as an identity partner in the US and internationally, addressing modern cybersecurity complexities.Speculative1 report
-
Market growth driven by Fabry disease treatment demand involving Amicus Therapeutics and Sanofi.Some support1 report
-
Bradley Campbell was appointed President and CEO of Amicus Therapeutics on July 31, 2025.Some support1 report
-
Amicus Therapeutics has expanded its geographic reach, announcing operations in European countries and Japan.Some support1 report
-
Amicus Therapeutics earned Zacks Rank #2 following promising estimate revisions.Some support1 report
-
Amicus Therapeutics began using LinkedIn for company presence on August 29, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Amicus Therapeutics this week
News at the entities that move Amicus Therapeutics most-
BioMarin Pharmaceutical StructuralInvestors are comparing the financial performance metrics of BioMarin Pharmaceutical and Metagenomi.Moves Amicus Therapeutics
-
TD Cowen Mentioned togetherAnalyst downgraded Ag Growth International Inc. due to debt management risks.Moves Amicus Therapeutics
-
U.K. Shared contextUK police are currently investigating plots targeting Iran.Moves Amicus Therapeutics
-
LinkedIn OperationalBoth LinkedIn and Google are currently being utilized as platforms for news distribution.Moves Amicus Therapeutics
Connections
The 6 strongest of 36, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
BioMarin Pharmaceutical Structural
BioMarin acquired Amicus Therapeutics, establishing a parent-subsidiary relationship and integrating its products.
-
Bradley Campbell Structural
Bradley Campbell serves as the President and CEO of Amicus Therapeutics.
-
U.K. Shared context
Amicus Therapeutics operates and experiences regulatory impacts within the U.K. market.
-
TD Cowen Mentioned together
TD Cowen provides investment ratings and analysis on Amicus Therapeutics.
-
LinkedIn Operational
Amicus Therapeutics utilizes LinkedIn for its company presence.
-
ERT Operational
Amicus Therapeutics is conducting research using a cohort related to ERT.
History
Events by the month they beganJune 2026
8 events- Amicus Therapeutics received drug approvals in multiple countries, including the US, Japan, Canada, and Switzerland.
- Amicus Therapeutics received MHLW approval in Japan for Pombiliti + Opfolda treatment for LOPD.
- Okta operates as an identity partner in the US and internationally, addressing modern cybersecurity complexities.
- Market growth driven by Fabry disease treatment demand involving Amicus Therapeutics and Sanofi.
- Bradley Campbell was appointed President and CEO of Amicus Therapeutics on July 31, 2025.
- Amicus Therapeutics has expanded its geographic reach, announcing operations in European countries and Japan.
- Amicus Therapeutics earned Zacks Rank #2 following promising estimate revisions.
- Amicus Therapeutics began using LinkedIn for company presence on August 29, 2025.